Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 6;7(36):58001-58006.
doi: 10.18632/oncotarget.11156.

KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review

Bum Jun Kim  1 , Hyun Joo Jang  2 , Jung Han Kim  1 , Hyeong Su Kim  1 , Jin Lee  2
Affiliations
Review

KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review

Bum Jun Kim et al. Oncotarget. .

Abstract

Ampullary adenocarcinoma (A-AC) is a rare malignancy arising from the ampulla of Vater. KRAS mutation is detected in 30-40% of patients with A-AC, but its clinical implication and prognostic value are not well described. We conducted this meta-analysis to investigate the association between KRAS mutation and prognosis in patients with A-AC. We searched Pubmed, MEDLINE, EMBASE, and the Cochrane Library databases for articles including following terms in their titles, abstracts, or keywords: 'ampullary or periampullary or ampulla of vater', 'cancer or carcinoma', and 'KRAS'. There were five studies with survival data of patients. A total of 388 patients with A-AC from the 5 studies were included in the overall survival (OS) analysis, and 169 patients from 2 studies were eligible for the relapse-free-survival (RFS) analysis. Out of 388 patients, 175 (45%) had KRAS mutation. There was no association between KRAS mutation and OS (HR = 1.06, 95% CI: 0.87-1.29, P = 0.58). However, there was a significant correlation between KRAS mutation and worse RFS (HR = 2.74, 95% CI: 1.52-4.92, P = 0.0008). In conclusion, this meta-analysis indicates that KRAS mutation is associated with poor RFS, but not with OS in patients with A-AC.

Keywords: KRAS mutation; ampullary adenocarcinoma; meta-analysis; prognosis.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Flow diagram of search process
Figure 2
Figure 2. Forest plots for the relation between KRAS mutation and survival outcomes
(A) The relation between KRAS mutation and overall survival. (B) The relation between KRAS mutations and relapse-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Benhamiche AM, Jouve JL, Manfredi S, Prost P, Isambert N, Faivre J. Cancer of the ampulla of Vater: results of a 20-year population-based study. Eur J Gastroenterol Hepatol. 2000;12:75–9. - PubMed
    1. Adsay V, Ohike N, Tajiri T, Kim GE, Krasinskas A, Balci S, Bagci P, Basturk O, Bandyopadhyay S, Jang K-T, Kooby DA, Maithel SK, Sarmiento J, et al. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. 2012;36:1592–608. - PubMed
    1. Balachandran P, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK. Long-term survival and recurrence patterns in ampullary cancer. Pancreas. 2006;32:390–5. - PubMed
    1. Kayahara M, Ohta T. Gross appearance of the ampullary tumor predicts lymph node metastasis and outcome. Dig Surg. 2010;27:127–31. - PubMed
    1. Roh Y-H, Kim Y-H, Lee H-W, Kim S-J, Roh M-S, Jeong J-S, Jung G-J. The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology. 2007;54:1641–4. - PubMed

Substances